A. Capello

Anticancer activity of targeted proapoptotic peptides.

B. Bernard, E. Krenning, A. Capello, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy

B. Bernard, E. Krenning, M. Jong, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Anticancer activity of modified somatostatin analogs

A. Capello, 2005 .

Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.

B. Bernard, E. Krenning, A. Capello, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

B. Bernard, E. Krenning, A. Capello, 2004, Cancer biotherapy & radiopharmaceuticals.

Expression of p53 as predictor for the development of esophageal cancer in achalasia patients.

E. Steyerberg, P. Siersema, H. van Dekken, 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma

E. Kuipers, P. Siersema, H. van Dekken, 2011, BMC gastroenterology.

Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.

E. Krenning, A. Capello, M. de Jong, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

B. Bernard, E. Krenning, A. Capello, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Bile Acid-Stimulated Expression of the Farnesoid X Receptor Enhances the Immune Response in Barrett Esophagus

E. Kuipers, P. Siersema, A. Capello, 2008, The American Journal of Gastroenterology.

Anti‐tumor effect and increased survival after treatment with [177Lu‐DOTA0,Tyr3]octreotate in a rat liver micrometastases model

B. Bernard, E. Krenning, C. V. van Eijck, 2003, International journal of cancer.

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

B. Bernard, E. Krenning, A. Capello, 2003, Cancer Biotherapy and Radiopharmaceuticals.

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

F. Forrer, B. Bernard, E. Krenning, 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin.

H. Burger, A. Capello, J. Brouwer, 2000, Biochemical and biophysical research communications.

Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

Marion de Jong, Mark Konijnenberg, B. Bernard, 2004, Cancer biotherapy & radiopharmaceuticals.